Carna Biosciences (TSE:4572) NonCurrent Deferred Liabilities: 円0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4572 Carna Biosciences Inc TSE:4572
42 GF Score
Price 円302.00
GF Value 円186.53
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Carna Biosciences NonCurrent Deferred Liabilities?

Carna Biosciences TSE:4572 -1.31% 42 NonCurrent Deferred Liabilities is 円0.0 Mil as of Dec. 2025. GuruFocus rates TSE:4572 with a GF Score™ of 42/100 and a GF Value™ of 円186.53 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Carna Biosciences's non-current deferred liabilities for the quarter that ended in Dec. 2025 was 円0.0 Mil.

Carna Biosciences NonCurrent Deferred Liabilities Related Terms

Carna Biosciences NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Carna Biosciences's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carna Biosciences NonCurrent Deferred Liabilities Chart

Carna Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Carna Biosciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4572
42GF Score
Carna Biosciences Inc TSE:4572
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of 円0.0 Mil mean?
Carna Biosciences (TSE:4572) has a NonCurrent Deferred Liabilities of 円0.0 Mil as of Dec. 2025. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Carna Biosciences and its competitors.
Is Carna Biosciences' NonCurrent Deferred Liabilities too high?
Carna Biosciences' current NonCurrent Deferred Liabilities is 円0.0 Mil. Overall, Carna Biosciences has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Carna Biosciences' NonCurrent Deferred Liabilities compare to VRTX and REGN?
Carna Biosciences' NonCurrent Deferred Liabilities of 円0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Carna Biosciences and its competitors. Carna Biosciences's current NonCurrent Deferred Liabilities is 円0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carna Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Carna Biosciences (TSE:4572) is currently considered Significantly Overvalued. The stock's GF Value™ is 円186.53, compared to a current price of 円302.00 — trading 61.9% above its estimated fair value. The current NonCurrent Deferred Liabilities is 円0.0 Mil. Carna Biosciences' overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Carna Biosciences (TSE:4572), the current NonCurrent Deferred Liabilities is 円0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carna Biosciences (TSE:4572) Overvalued in 2026?

Based on GuruFocus' analysis, Carna Biosciences stock appears to be overvalued. The current stock price of 円302.00 is trading 61.9% above its estimated GF Value™ of 円186.53. GuruFocus considers Carna Biosciences to be Significantly Overvalued.

Key valuation signals for TSE:4572:

  • NonCurrent Deferred Liabilities: 円0.0 Mil
  • GF Value™: 円186.53 vs. price of 円302.00 (61.9% above fair value)
  • GF Score™: 42/100 with 5 warning signs

No single metric tells the full story. See the TSE:4572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carna Biosciences Business Description

Address BMA 3F 1-5-5 Minatojima-Minamimachi, Kobe, JPN, 650-0047
Carna Biosciences Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines for the treatment of cancer and inflammatory diseases using own kinase drug discovery platform, QuickScout.
42GF Score

Get the complete analysis for TSE:4572

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円302.00
Price
円186.53
GF Value